

RESEARCH

Open Access



# Insights into the genetics of menopausal vasomotor symptoms: genome-wide analyses of routinely-collected primary care health records

Katherine S. Ruth<sup>1\*</sup>, Robin N. Beaumont<sup>1</sup>, Jonathan M. Locke<sup>1</sup>, Jessica Tyrrell<sup>1</sup>, Carolyn J. Crandall<sup>2</sup>, Gareth Hawkes<sup>1</sup>, Timothy M. Frayling<sup>1</sup>, Julia K. Prague<sup>3,4</sup>, Kashyap A. Patel<sup>3,4</sup>, Andrew R. Wood<sup>1</sup>, Michael N. Weedon<sup>1</sup> and Anna Murray<sup>1</sup>

## Abstract

**Background** Vasomotor symptoms (VMS) can often significantly impact women's quality of life at menopause.

In vivo studies have shown that increased neurokinin B (NKB) / neurokinin 3 receptor (NK3R) signalling contributes to VMS, with previous genetic studies implicating the *TACR3* gene locus that encodes NK3R. Large-scale genomic analyses offer the possibility of biological insights but few such studies have collected data on VMS, while proxy phenotypes such as hormone replacement therapy (HRT) use are likely to be affected by changes in clinical practice. We investigated the genetic basis of VMS by analysing routinely-collected health records.

**Methods** We performed a GWAS of VMS derived from linked primary-care records and cross-sectional self-reported HRT use in up to 153,152 women from UK Biobank, a population-based cohort. In a subset of this cohort ( $n=39,356$ ), we analysed exome-sequencing data to test the association with VMS of rare deleterious genetic variants. Finally, we used Mendelian randomisation analysis to investigate the reasons for HRT use over time.

**Results** Our GWAS of health-records derived VMS identified a genetic signal near *TACR3* associated with a lower risk of VMS (OR=0.76 (95% CI 0.72,0.80) per A allele,  $P=3.7\times 10^{-27}$ ), which was consistent with previous studies, validating this approach. Conditional analyses demonstrated independence of genetic signals for puberty timing and VMS at the *TACR3* locus, including a rare variant predicted to reduce functional NK3R levels that was associated with later menarche ( $P=5\times 10^{-9}$ ) but showed no association with VMS ( $P=0.6$ ). Younger menopause age was causally-associated with greater HRT use before 2002 but not after.

**Conclusions** We provide support for *TACR3* in the genetic basis of VMS but unexpectedly find that rare genomic variants predicted to lower NK3R levels did not modify VMS, despite the proven efficacy of NK3R antagonists. Using genomics we demonstrate changes in genetic associations with HRT use over time, arising from a change in clinical practice since the early 2000s, which is likely to reflect a switch from preventing post-menopausal complications in women with earlier menopause to primarily treating VMS. Our study demonstrates that integrating routinely-collected primary care health records and genomic data offers great potential for exploring the genetic basis of symptoms.

\*Correspondence:

Katherine S. Ruth

K.S.Ruth@exeter.ac.uk

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Keywords** Vasomotor symptoms, Menopause, Hormone replacement therapy, Genome-wide analyses, Genome-wide association study

## Introduction

Vasomotor symptoms (VMS) in postmenopausal women include hot flashes and night sweats, which can have debilitating and long-lasting effects on quality of life, with 10% of women experiencing VMS for up to 12 years [1]. Hormone replacement therapy (HRT) is the most effective treatment for VMS around menopause but its popularity amongst the public and health professionals declined following the publication of adverse outcome data [2] and it is contraindicated in some women, such as those who have had breast cancer. Consequently, there is great interest in identifying non-oestrogen drug treatments for VMS.

VMS result from dysfunction of thermoregulation by the hypothalamus and autonomic thermoregulatory system caused by increased neurokinin B (NKB)/neurokinin 3 receptor (NK3R; also known as the neuromedin-K receptor or tachykinin receptor 3) signalling in response to decreased circulating oestradiol levels, as shown in vivo in animal models [3, 4]. Four Phase 2 clinical trials have demonstrated that administration of a NK3R receptor antagonist results in a clinically significant reduction in hot flashes comparable to that achieved by HRT [5–8]. Such NK3R receptor antagonists are currently in Phase 3 clinical trials and have not yet come to market [9]. Neurokinin signalling also plays an important role in controlling the onset of puberty [10], with genetic variants that knock out the *TACR3* gene (which encodes NK3R) resulting in pubertal failure in homozygous carriers [11, 12] and delayed puberty in heterozygous carriers [13]. A genome-wide association study (GWAS) in 17,695 women (12,276 with VMS) identified a genetic signal for VMS in the *TACR3* gene region [14], further replicated in a GWAS of oestrogen-replacement use [15]. Additionally, population-based genome-wide association studies (GWAS) have identified several more common genetic variants in or near the *TACR3* gene associated with normal variation in age at menarche [16].

We aimed to improve understanding of the genetic basis of VMS through genomic analyses. Few cohort studies with genetic data have collected self-reported information on VMS, thus we adopted a novel approach by deriving this phenotype from primary care health records in 92,028 women in UK Biobank [17, 18], a five-fold increase in sample size.

## Methods

### Phenotype definitions

Between 2006–2010, UK Biobank recruited over 500,000 individuals aged 37–73 years from across the UK who answered detailed questions about themselves, had measurements taken and provided blood, urine and saliva sample samples, and for whom linked health records data are available [18]. We identified women with VMS for inclusion in our primary analyses from linked primary care records, which are available for ~45% of the cohort and capture participants' contact with health care professionals working at UK general practices (family physicians) over their lifetime to ~2017. Cases ( $n=14,261$ ) were women with one or more clinical events in the linked primary care records (e.g. symptoms, history or diagnosis) containing any of 33 relevant codes for menopausal VMS (Supplementary Methods; Supplementary Table 1). These codes were identified by reviewing 970 Read v2 and CTV3 codes with descriptions containing the full and partial words “flush”, “flash”, “meno”, “sweat”, “vaso” for relevance and frequency of use in females in UK Biobank. Controls ( $n=77,767$ ) were women who were included in the linked primary care records (identified through having a primary care registration record without a relevant VMS code), and aged 50 and over at the baseline UK Biobank assessment and so were likely to be experiencing the menopause transition and thus at risk of VMS.

For secondary analyses we derived proxy phenotypes for VMS based on self-reported HRT use (Supplementary Methods, Supplementary Table 2). To explore the effect of the publication of adverse health outcomes relating to HRT, we further subdivided the ever taking HRT group into those who took HRT before and after 2002 to reflect the year of publication of the initial findings of the Women's Health Initiative HRT trial [19] and estimated the proportion of women taking HRT before and after 2002 (Supplementary Methods, Supplementary Table 2).

### Genome-wide association study analyses

Genotyping of the UK Biobank study was performed centrally [17]. Two genotyping arrays with over 95% common marker content were used to genotype the individuals; the Affymetrix Axiom UK Biobank array (~450,000 individuals) and the UKBiLEVE array (~50,000 individuals). This dataset underwent extensive central quality control and genotype imputation using 1000 Genomes Phase 3/

UK10K and Haplotype Reference Consortium reference panels. We based our study on 451,099 individuals who we identified as being of European descent, as described previously [20].

We carried out genome-wide analyses using BOLT-LMM v2.3 [21], which uses a mixed linear model to account for relatedness and ethnicity. We tested 17 million genetic variants with minor allele frequency (MAF) > 0.1% and imputation quality > 0.3. Association testing was based on an additive model and was adjusted for genotyping chip and release of the data, recruitment centre and age (Supplementary Methods). Quantitative traits were inverse-rank normalised, to ensure that residuals were normally distributed. Genome-wide significant variants had  $P < 5 \times 10^{-8}$ . For case-control traits we transformed effect sizes ( $\beta$ ) on the quantitative scale to odds ratios (using the transformation  $\ln(\text{OR}) = \beta / (\mu \times (1 - \mu))$ , where  $\mu$  is the fraction of cases) and confirmed associations using a Fisher's exact test (Supplementary Methods). We performed case-control matched analyses of HRT use to account for different age distributions (Supplementary Methods). Independent signals were more than 500 kb from the next most significant variant for the same phenotype and were uncorrelated ( $r^2$  measure of linkage disequilibrium (LD) < 0.5) with signals for other VMS phenotypes. Additionally, to identify further independent signals at the *TACR3* locus, we carried out conditional analysis by re-running the VMS GWAS including the genotype at the lead variant as a covariate.

We meta-analysed the results of the VMS GWAS with summary statistics from the European cohorts (GARNET and WHIMS) of Crandall et al. [14] (5,195 cases and 2,990 controls). Inverse-variance weighted meta-analyses were carried out in METAL [22] with genomic-control correction applied and we included variants with MAF > 0.1% and imputation quality > 0.3.

#### **In silico analyses and annotation of GWAS signals**

To identify variants with functional or regulatory consequences, we looked up variants in LD with our lead genetic variant in Variant Effect Predictor (build 38) [23], Ensembl (Human (GRCh38.p13 release 100) [24], HaploReg v4.1 [25] and goDMC (<http://mqtldb.godmc.org.uk/>). We investigated eQTLs in  $r^2 > 0.8$  with the top hits in PsychENCODE [26] and GTEx v8 (<https://www.gtexportal.org/home>). We calculated the distance of variants in  $r^2 > 0.8$  with the lead genetic variant to canonical and alternative splice sites for *TACR3* using Intropolis [27]. LD was calculated from best guess genotypes for 1000 Genomes Phase 3/HRC imputed variants in ~ 340,000 unrelated UK Biobank participants of white British ancestry using PLINK v1.9 [28]. Manhattan and

quantile-quantile plots were produced in R using the package "qqman" [29]. LocusZoom v1.4 [30] was used to plot the association statistics at individual loci.

#### **Exome-wide analyses**

We carried out gene burden association testing of rare variants using exome sequencing data in 184,431 individuals of European ancestry from UK Biobank [31] (Supplementary Methods). Variants in CCDS transcripts were annotated using Variant Effect Predictor [23] and we identified loss-of-function (LOF) variants (stop-gain, frameshift, or abolishing a canonical splice site (-2 or +2 bp from exon, excluding the ones in the last exon)) deemed to be high confidence by LOFTEE (<https://github.com/konradjk/loftee>). We conducted gene-burden analyses using SAIGE-GENE [32] for age at menarche and REGENIE [33] for VMS (different software was used due to updated analyses pipelines for computational reasons), which both account for relatedness and ethnicity and are suitable for analyses with unbalanced case:control ratios. We included recruitment centre and age at baseline as covariates and tested the association of variants with MAF < 0.001 in *TACR3* (transcript ENST00000304883) in aggregate as well as individually (Supplementary Table 3).

#### **Tests of associations of variants in the *TACR3* region**

We investigated whether puberty timing genetic variants in/near the *TACR3* gene were also associated with VMS. These variants included a rare protein truncating variant which in homozygous state leads to hypogonadotropic hypogonadism and in heterozygous state to delayed menarche (rs144292455 C>T p.W275X, chr4:104577415, MAF=0.06%) [13, 34] and five genetic variants associated with age at menarche in GWASs (rs55784701 (chr4:104247262), rs3733632 (chr4:104640935), rs62342064 (chr4:104665972), rs115260227 (chr4:104774698), rs17035311 (chr4:106066293), smallest MAF 1.3%) within ~ 1.5 Mb of *TACR3* [16]. Genotypes were extracted from imputed data except for rs144292455, which is a rare variant and thus poorly imputed; for this variant we used directly genotyped data, which have previously been shown to be reliable [35]. We tested the associations of these variants individually, in combination and when adjusted for genotype of our lead VMS genetic variant using regression analyses. We performed logistic (binary traits) and linear (quantitative traits) regression in Stata v14.0/v16.0 in 379,768 unrelated individuals of European descent [36]. We regressed outcomes on genotype including the covariates genotyping chip and release of genotype data, recruitment centre, age and the first five genetic principal components (generated as described previously [36]).

### Mendelian randomisation analyses

We used Mendelian randomisation (MR) analyses to test whether earlier age at menopause was the cause of women taking HRT, or just correlated with HRT use. We constructed a genetic instrument for the exposure age at menopause from 56 published genetic variants discovered in a meta-analysis of ~70,000 women that was independent of UK Biobank data [37]. Outcomes were based on our GWAS in UK Biobank. In each MR test we assessed a number of widely used methods including inverse-variance weighted MR (IVW MR) and those more robust to pleiotropy (weighted median MR, penalised weighted median MR and MR-Egger [38, 39]) to address the assumption that alleles that influence the exposure do not influence the outcome via any pathway other than through the exposure. We used IVW MR as our primary analysis method and interpreted directionally-consistent results across the various methods as strengthening our causal inference.

### Heterogeneity in effects of genetic variants before and after 2002

Following the publication of data on adverse effects of HRT in 2002, we hypothesized that the primary reasons

why women took HRT changed before and after this date, and that these differences would be reflected in genetic associations. To test this, for genetic signals identified for HRT phenotypes, we compared the association of the lead variant with ever using HRT before and after 2002 by comparing the direction and calculating a heterogeneity chi-squared *P*-value using the package “metan” in Stata v14.0/v16.0. We carried out Mendelian randomisation (as described) to test the association of genetically-instrumented age at menopause with HRT use before and after 2002.

## Results

### Validation of VMS phenotype


We identified 14,261 women with VMS and 77,767 controls from linked primary care records in UK Biobank for inclusion in our genome-wide association study (GWAS) of VMS (Table 1). From our GWAS we identified a single independent genetic signal (lead variant rs34867104) associated with lower odds of having VMS ((OR=0.78 (95% CI 0.74,0.82) per AT allele; allele frequency (AF)=5.5%;  $P=1.7 \times 10^{-20}$ ; imputation quality=0.99) (Supplementary Fig. 1, Fig. 1A). Meta-analysis of the UK Biobank VMS GWAS with

**Table 1** Descriptive statistics for demographic and reproductive characteristics of women included as cases and controls in GWAS of VMS phenotypes

	Vasomotor symptoms					Ever taken HRT				
	Cases		Controls		<i>P</i>	Cases		Controls		<i>P</i>
	N	Mean (SD) / % (n)	N	Mean (SD) / % (n)		N	Mean (SD) / % (n)	N	Mean (SD) / % (n)	
Age	14,261	56.08 (7.37)	77,767	60.55 (5.39)	<1E-50	72,622	61.82 (5.09)	80,686	59.6 (5.81)	<1E-50
Body mass index	14,209	27.25 (5.03)	77,489	27.31 (5.11)	0.20	72,371	27.04 (4.81)	80,417	27.00 (5.16)	0.15
Age at menarche	13,832	12.95 (1.6)	75,335	12.93 (1.57)	0.36	70,614	12.94 (1.57)	78,102	12.94 (1.54)	0.63
Age at natural menopause	4,956	50.17 (4)	42,920	50.47 (3.91)	3.0E-07	33,250	49.53 (4.33)	72,629	50.7 (3.74)	<1E-50
Number of births	14,253	1.80 (1.15)	77,719	1.90 (1.16)	4.0E-21	72,583	1.91 (1.14)	80,640	1.85 (1.18)	7.0E-23
Number of pregnancies	13,977	2.31 (1.56)	76,437	2.34 (1.54)	0.018	71,437	2.39 (1.54)	79,382	2.29 (1.55)	3.9E-32
Townsend deprivation index	14,241	-1.51 (2.9)	77,673	-1.57 (2.89)	0.022	72,544	-1.57 (2.91)	80,607	-1.62 (2.87)	6.6E-04
Smoking status	14,087		76,901		5.4E-27	71,709		79,915		
- Never		56.2% (7,912)		58.6% (45,057)			53.1% (38,102)		61.8% (49,351)	
- Previous		33.8% (4,768)		34.1% (26,208)			38.8% (27,845)		31.3% (25,023)	
- Current		10.0% (1,407)		7.3% (5,636)			8.0% (5,762)		6.9% (5,541)	
Vasomotor symptoms	14,261		77,767			33,015	16.8% (5,533)	36,106	7.5% (2,717)	<1E-50*
Ever taken HRT	8,250	67.1% (5,533)	60,871	45.1% (27,482)	<1E-50*	72,622		80,686		
Used HRT before 2002	6,779	59.9% (4,062)	55,748	40.1% (22,359)	<1E-50	57,740		80,686		
Used HRT after 2002	3,625	25.0% (908)	35,304	5.4% (1,915)	<1E-50	6,640		80,686		

All variables are at baseline except for age at menopause, which was calculated from the the most recent available visit. Ever taken HRT was defined in postmenopausal women and was identified by the answer to: “Have you ever used hormone replacement therapy (HRT)?”. For categorical variables, N is the total number of cases or controls with information; Age at menarche excludes values < 9 and > 17 years; Age at natural menopause excludes values < 40 and > 60 years. Townsend deprivation scores range from negative values to positive values with smaller scores indicating less material deprivation. *P*-values are from a t-test for continuous variables and a chi-square test (contingency table) for categorical variables

\* Indicates *P* value for chi-squared test for ever taken HRT vs vasomotor symptoms



**Fig. 1** Genetic associations at the *TACR3* region: **A** Associations with VMS in UK Biobank. GWAS signals for age at menarche and the *TACR3* LOF allele (rs144292455 C > T) were not associated with VMS at  $P < 5 \times 10^{-8}$  and show little correlation with the VMS signal ( $LD r^2 < 0.2$ ); **B** Associations with age at menarche in published GWAS. GWAS signals for age at menarche and the *TACR3* LOF allele (rs144292455 C > T) were strongly associated with age at menarche. The VMS lead variant shows association at  $P < 5 \times 10^{-8}$  with age at menarche in this univariate analysis though was not identified as an independent signal in published age at menarche GWAS. **C** Univariate and conditional association analyses in UK Biobank. The VMS lead variant was associated with age at menarche at  $P < 5 \times 10^{-8}$  in univariate analyses (“Single”) but this association attenuated in analysis adjusting for the genotypes of the age at menarche GWAS signals (“Conditional”). The *TACR3* LOF allele (rs144292455 C > T) was strongly associated with later age at menarche but not VMS. Notes: Variants shown are within  $\pm 400$  kb of rs34867104, the lead variant for VMS, and  $LD r^2$  shown is with rs34867104. Labelled variants are four variants associated with age at menarche within this region (triangles) [16], VMS (purple diamond) and also the LOF variant rs144292455 (triangle). For clarity, other variants with  $P > 1 \times 10^{-5}$  are not shown. Association statistics for rs144292455 were calculated in directly genotyped data in UK Biobank whereas all other statistics are from GWAS of imputed data. Association statistics for age at menarche GWAS are from published ReproGen meta-analyses excluding 23andMe [16]. Results presented in Fig. 1C are from analysis of directly genotyped data performed in 379,768 unrelated individuals adjusting for genetic principal components (Supplementary Table 5)

that from Crandall et al. [14] replicated the same single genetic signal in the *TACR3* gene (OR = 0.76 per A allele (95% CI 0.72, 0.80;  $P = 3.7 \times 10^{-27}$ ) (Table 2) with little evidence of heterogeneity ( $P = 0.025$ ), validating our primary care health records derived phenotype. No further independent signals at  $P < 5 \times 10^{-8}$  were identified when we performed GWAS conditioning on the genotype at the lead variant (rs34867104). Lead variant rs34867104 is intronic in *TACR3* and *in silico* analyses found little evidence to suggest a biological mechanism for the GWAS signal. There were no non-synonymous variants (with effects on protein sequence) strongly correlated with the signal ( $LD r^2 > 0.8$ ), and there was

little evidence for an effect on gene expression, regulation or splicing (Supplementary Results). However, based on clinical studies that have demonstrated that NK3R antagonists reduce VMS [5, 40, 41], *TACR3* is the most likely causal gene in this region.

**No effect on VMS of genetic variants predicted to reduce levels of NK3R**

Using exome sequencing data available for 6,280 women with VMS and 33,076 controls we investigated genetic variants in *TACR3* with alleles predicted to result in no protein product in homozygous individuals (i.e. LOF variants). We tested the association of LOF allele

**Table 2** Genetic signals for VMS from primary GWAS analysis and secondary analyses of HRT proxy phenotypes

Analysis	Variant id	Chr:pos (b37)	EA/OA (EAF)	Phenotype <sup>a</sup>	Effect (95% CI) per allele	P	Distance to nearest gene
Primary discovery	rs34867104	chr4:104561892	AT/A (0.055)	VMS	OR=0.78 (0.74,0.82)	$1.7 \times 10^{-20}$	<i>TACR3</i> (0)
Meta-analyses <sup>b</sup>	rs112390256	chr4:104575473	A/G (0.055)	VMS	OR=0.76 (0.72,0.80)	$3.7 \times 10^{-27}$	<i>TACR3</i> (0)
Secondary discovery	rs34867104	chr4:104561892	AT/A (0.055)	Ever taken HRT	OR=0.85 (0.82,0.87)	$1.1 \times 10^{-26}$	<i>TACR3</i> (0)
Secondary discovery	rs146705358	chr4:104579107	AGGAATGTG CACAT/A (0.036)	Age ended HRT	-0.07 (-0.1,-0.05)	$2.8 \times 10^{-8}$	<i>TACR3</i> (0)
Secondary discovery	rs200480420	chr6:135016903	A/AT (0.999)	Time taken HRT	-0.51 (-0.69,-0.33)	$4.3 \times 10^{-8}$	<i>LINC01010</i> (+191.7 kb)
Secondary discovery	rs7830431	chr8:10700317	G/A (0.597)	Age started HRT	0.03 (0.02,0.04)	$2.9 \times 10^{-8}$	<i>PINX1</i> (+2.9 kb)

Chr chromosome, CI confidence interval, EA effect allele, EAF effect allele frequency, HRT hormone replacement therapy, OA other allele, OR odds ratio, pos position, VMS vasomotor symptoms

<sup>a</sup> Units for age started, ended and time taken HRT are standard deviations of the inverse rank transformed phenotype

<sup>b</sup> Variant rs112390256 represents the same genetic signal in *TACR3* as that identified from the primary discovery analysis since it is in linkage disequilibrium with rs34867104 (LD  $r^2=0.99$ ), which was not analysed in the earlier study

rs144292455 C>T p.W275X (MAF=0.06%) previously reported as associated with delayed menarche [13, 34] and all rare (MAF<0.1%) LOF variants in *TACR3* in aggregate. There was little evidence of an association between *TACR3* LOF and VMS (rs144292455  $P=0.6$ , 8/41 carriers were VMS cases vs 6,272/39,315 non-carriers; aggregate LOF burden  $P=0.9$ , 8/49 carriers were VMS cases vs 6,272/39,307 non-carriers), though *TACR3* LOF was associated with delayed age at menarche (rs144292455  $P=5.0 \times 10^{-9}$ , 105 carriers vs 98,386 non-carriers; aggregate LOF burden  $P=8.6 \times 10^{-11}$ , 128 carriers vs 98,363 non-carriers) (Supplementary Table 4). All carriers of the LOF alleles were heterozygous and so would be expected to have reduced levels of *TACR3* protein. Associations of rs144292455 with VMS and age at menarche were consistent when we repeated the analysis in a larger sample of directly genotyped chip data (18/79 carriers were VMS cases vs 11,832/76,335 non-carriers) (Supplementary Table 5). We further confirmed the independence of the VMS GWAS signal (rs34867104) and rs144292455 through conditional analyses (Supplementary Table 5).

#### Independent genetics of puberty timing and VMS at *TACR3*

We investigated the association with VMS of five common/low frequency genetic variants (smallest MAF 1.3%) in/near *TACR3* which have been associated with puberty timing in GWAS [16]. These five variants were not associated with VMS ( $P>0.02$  for all) and showed little correlation with the VMS signal rs34867104 (LD  $r^2 \leq 0.12$  for all) (Fig. 1A and B). The VMS signal (rs34867104) was associated with age at menarche (Fig. 1B, Supplementary Table 6) [16], but conditioning on the five genetic variants for age at menarche attenuated the association ( $P=7.5 \times 10^{-16}$  in single variant analyses;  $P=2.9 \times 10^{-6}$  in

conditional analyses) (Fig. 1C, Supplementary Table 6), suggesting that rs34867104 does not represent an independent signal for menarche timing. Taken together with the analyses of LOF variants, our results suggest differences in the genetic architecture of age at menarche and VMS at the *TACR3* locus.

#### HRT proxy phenotype reflects menopause timing

Next we hypothesised that we could increase the number of cases included in our analyses five-fold by employing menopausal HRT use as a proxy phenotype for VMS, since this phenotype is available in self-reported data and HRT is predominantly used to treat menopausal symptoms. We identified variant rs34867104 as the most strongly associated signal (Table 2) (for ever taken HRT, OR=0.85 (95% CI 0.82,0.87) per AT allele,  $P=1.1 \times 10^{-26}$ ), with consistent results in age-matched sensitivity analyses (OR=0.83 (95% CI 0.80,0.86)). Our proxy phenotype analyses resulted in a further 14 independent genetic signals associated with HRT (age started and time taking) that did not reach genome-wide significance in the VMS GWAS (all  $P>0.05$ ) (Supplementary Results, Supplementary Table 7). All of these 14 signals had imputation quality  $>0.9$ . We explored previously reported associations for menopause timing at these signals to test the validity of this approach finding that 11 of the 14 signals represented associations with HRT as a consequence of early menopause (Supplementary Table 7). In contrast, the VMS signal at *TACR3* (rs34867104) was not associated with menopause timing. Three additional genetic signals near *C3orf43*, *LINC01010* and *PINX1* were not associated with menopause timing and represent putative VMS signals. To test whether there was a causal association between menopause timing and using HRT, we performed Mendelian

randomisation analyses. A one-year genetically-instrumented earlier age at menopause was strongly associated with higher odds of taking HRT (OR=1.10 (1.08,1.12),  $P=1 \times 10^{-18}$ ) (Supplementary Table 8) but showed little association with VMS ( $P>0.05$ ). Overall, these genetic analyses show that the HRT use phenotype does capture VMS, but not specifically.

**Genetics capture changes in characteristics of women using HRT**


In UK Biobank we identified a change in the proportion of women using HRT from 49% before 2002 to 14% after 2002. We hypothesized that the publication of adverse trial results for HRT in 2002 would result in differences in the characteristics of women taking HRT before and after this time that would be reflected in genetic associations, while associations due to underlying biology of VMS should remain similar. The signals that were associated with HRT as a result of menopause timing had opposite effects on HRT use before and after 2002 (Supplementary Table 9), whereas the genetic signal in *TACR3* (rs34867104) was associated consistently over time (before 2002, OR=0.85 per AT allele (95% CI 0.83,0.88),  $P=1.6 \times 10^{-21}$ ; after 2002, OR=0.83 per AT allele (95% CI 0.77,0.89),  $P=1.4 \times 10^{-6}$ ; P test of heterogeneity=0.48). Two of the putative VMS signals (rs201598433 near *C3orf43* and rs200480420 near *LINC01010*) also showed little evidence of heterogeneity in effects pre/post 2002 (Supplementary Table 9), strengthening the support for being candidate VMS

signals (Table 2). By testing the association of genetically-instrumented age at menopause with HRT use before and after 2002, we found that a one-year genetically-predicted earlier menopause raised the odds of HRT use before 2002 (OR=1.12, 95% CI=1.10,1.13), but not after (OR=0.98, 95% CI=0.95,1.00) (Fig. 2), with concordant results in age-matched sensitivity analyses (Supplementary Table 8).

**Discussion**

In this large study of menopausal VMS derived from primary care health records, we demonstrate the potential of routine health care data for deriving phenotypes not available in self-reported study data. We provide further evidence to support the role of *TACR3* in the genetic basis of VMS [14] and identified considerable phenotypic and genetic heterogeneity at the *TACR3* locus that should be explored further to provide important insight into potential therapies targeted at *TACR3*. We demonstrate that HRT phenotypes can be used as a proxy for VMS, provided that analyses consider the impact on genetic associations of major changes in the use of that therapy in routine clinical practice. Based on our results we suggest that HRT use post-2002 is more appropriate for capturing severe menopausal symptoms than pre-2002 use.

We replicated a genetic signal in *TACR3* associated with VMS [14], adding to genetic evidence for a role of NK3R (coded for by *TACR3*) in VMS. In postmenopausal women, oestrogen withdrawal results in hypertrophy of kisspeptin-neurokinin B-dynorphin secreting (KNDy)



**Fig. 2** Effect of age at natural menopause on HRT use: **A** before 2002; and **B** after 2002. Mendelian randomisation analyses showing effect of genetic instrument for age at menopause on odds of using HRT

neurons in the infundibular nucleus of the hypothalamus, which increase mRNA expression of NKB, dynorphin, kisspeptin, substance P and ER $\alpha$  [42]. Studies in rodents have shown that increased levels of NKB result in more signalling through NK3R, stimulating pre-optic thermoregulatory areas of the hypothalamus but do not entirely exclude contributions of other KNDy peptides to thermoregulation (i.e. dynorphin, kisspeptin and substance P) [3, 4]. In humans, previous studies have demonstrated that infusion of NKB in pre-menopausal women induces menopausal VMS [41] and, in clinical trials, that NK3R antagonists reduce VMS in menopausal women [5, 40, 41], providing support for *TACR3* as the most likely causal gene in the GWAS locus. However, our *in silico* analyses found no additional evidence to confirm *TACR3* as the causal gene and we identified no reduction in VMS in 41 heterozygous carriers of a rare LOF genetic variant in *TACR3* (rs144292455) [34, 43] in whom NK3R expression should be reduced. Thus we cannot rule out the possibility that *TACR3* is not the causal gene for the VMS GWAS signal and that the GWAS signal is tagging a variant with an effect on another gene. Other published GWAS studies have identified significant signals in *TACR3* associated with testosterone levels (in males, and males and females combined) [44], and near *TAC3* (which codes for NKB) associated with age at menopause [45]. Further expanded genomic analyses of VMS and related phenotypes and the increasing availability of additional genomic data will allow these inconsistencies to be explored.

We provide evidence that the mechanism through which the genetic variants in *TACR3* influence VMS are distinct from effects of variants in this genomic region on puberty timing, consistent with known biology supporting distinct pathways. At puberty, NKB signalling is involved in the activation of Kiss1 neurons, resulting in pulsatile secretion of kisspeptin and consequently gonadotropin releasing hormone and luteinising hormone [10]. The rare variant in *TACR3* tested in our analyses (rs144292455) causes a premature stop codon (p.W275X) in the fifth transmembrane segment of the 465 amino acid NK3R and is predicted to be pathogenic and cause loss of function [34, 43]. Variant rs144292455 causes idiopathic hypogonadotropic hypogonadism in male homozygotes [34] and the rare allele shows additive effects, delaying menarche by 1.25 years in female heterozygotes [13, 35], an effect confirmed in our study cohort despite the lack of association with VMS. One explanation for these apparently contradictory results could be that complete inhibition of NK3R signalling [46] might be required to reduce VMS, and that the heterozygous women in our analyses still had sufficient NKB/NK3R signalling to cause VMS, resulting in

no discernible reduction in symptoms. In contrast, we suggest that puberty timing appears to be sensitive to the amount of NKB/NK3R signalling. We were unable to test the effects of homozygous LOF of rs144292455 on VMS, as there were no such women in our study cohort. Common genetic variation associated with age at menarche at the *TACR3* locus is independent of rare variant rs144292455 [13] and was also not associated with VMS. We propose that changes in gene regulation and expression mediate the VMS phenotype, potentially through alterations in transcription factor binding, rather than the direct effects on NK3R, and that this should be explored in future studies.

We demonstrate an interaction between a major change in clinical practice and genetic determinants for HRT use, adding to the relatively small number of robust gene-by-environment interactions in the literature. Overall, women with earlier menopause were more likely to use HRT, but prior to 2002, earlier age at menopause increased the odds of HRT use but this relationship did not exist after 2002. In contrast, the genetic signal for VMS use in *TACR3* (rs34867104) remained associated with using HRT across the time period and was not associated with menopause timing. We suggest that prior to 2002, as recommended at the time, women took HRT as a routine treatment to relieve menopausal symptoms and also to prevent complications secondary to oestrogen depletion, for example, reduced bone mineral density. After 2002, we postulate that only women with severe VMS took HRT due to perceived risks that led to an aversion of women, health professionals and clinical guidelines to HRT [47]. It is surprising that earlier age of menopause was not associated with HRT use after 2002, as typically HRT will still be recommended until the average natural age of menopause for women with an early age of menopause. The lack of association of age at menopause with HRT use post 2002 highlights a possible potential under usage of HRT in the UK that requires further investigation. Current UK National Institute for Health and Care Excellence guidance is that HRT should be considered as a treatment for VMS [48] and our analysis suggests that HRT may now be underutilised among such women. Our findings suggest that genetic associations with HRT use that do not change over time are likely to be within the causal pathway for VMS.

Our analyses were carried out in UK Biobank, in which there are known biases towards healthy and more affluent individuals [49], in individuals who were similar to European genetic reference populations, highlighting a need for replication in other cohorts and ancestries. The impact of changes to clinical practice regarding HRT use may not be the same in all populations and future analyses must be mindful of other such gene by environment



interactions. Currently, linked primary care data in UK Biobank are limited to approximately half the cohort and the coding of VMS depends on women consulting a GP with symptoms, and on these being recorded. Inclusion of women with VMS without a GP record as controls in our analyses will have resulted in reduced statistical power, but not false positives. The proxy phenotype of taking HRT did not distinguish between types of medication and is based on retrospectively collected questionnaire data, which may be subject to recall bias. However, another published study that analysed self-reported medication data in UK Biobank identified the same genetic signal for HRT use [15].

By identifying genetic associations with VMS and with the proxy phenotype HRT use we replicated a genetic signal for VMS in *TACR3* and identified a further two signals that require replication. We identified time-dependent genetic associations for HRT use that were associated with menopause timing but not VMS, providing insights into the factors driving treatments and allowing refinement of a proxy phenotype for VMS, i.e. HRT use after 2002. Despite the strong evidence for a role of *TACR3* in VMS from clinical trials of NK3R antagonist treatments, our study highlights limitations in current understanding that should be addressed in future studies to further benefit the development of therapies for these common, potentially life-changing symptoms.

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12920-023-01658-w>.

**Additional file 1: Supplementary Methods. Supplementary Results. Supplementary Figure 1.** Quantile-quantile and Manhattan plots for the GWAS of VMS in UK Biobank. **Supplementary Figure 2.** Quantile-quantile and Manhattan plots of the GWASs of HRT use.

**Additional file 2: Supplementary Table 1.** Read v2 and CTV3 codes used to identify women with vasomotor symptoms. **Supplementary Table 2.** Numbers of women included in the genome-wide analyses. **Supplementary Table 3.** Loss-of-function variants in *TACR3* identified in analysis of UK Biobank exome sequencing data. **Supplementary Table 4.** Results of gene burden and single variant analyses of *TACR3* in exome sequencing data from UK Biobank. **Supplementary Table 5.** Comparison of the effects on VMS and age at menarche of rs34867104 (GWAS signal) and rs144292455 (rare loss of function variant) in *TACR3*. **Supplementary Table 6.** Conditional analyses of variants in *TACR3* associated with VMS and age at menarche. **Supplementary Table 7.** Genetic signals identified by GWAS of HRT phenotypes. **Supplementary Table 8.** Results of Mendelian randomisation analyses of association of age at menopause with HRT use. **Supplementary Table 9.** Heterogeneity in effect of genetic variants on HRT use before and after 2002. **Supplementary Table 10.** PsychENCODE brain eQTL data for *TACR3*.

## Acknowledgements

The authors would like to acknowledge the use of the University of Exeter High-Performance Computing (HPC) facility in carrying out this work.

## Authors' contributions

AM and KSR designed the study. KSR led the data analysis with contributions from RNB, JML, JT, GH and ARW. AM, KSR, RNB, JT, GH, ARW, MNW and TMF

had access to the underlying UK Biobank data. CJC provided data for the VMS meta-analysis. KSR, JKP, KAP, TMF, MNW and AM reviewed and interpreted the results. KSR and AM wrote the first draft of the report. All authors reviewed the drafts and contributed to the revision of the report.

## Funding

KSR is supported by Cancer Research UK [grant number C18281/A29019]. JKP is supported by the UKRI Expanding Excellence in England award.

This project utilised high-performance computing funded by the UK Medical Research Council (MRC) Clinical Research Infrastructure Initiative (award number MR/M008924/1).

This study was supported by the National Institute for Health and Care Research Exeter Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

The funders of the study had no role in the design, data collection, data analysis, data interpretation or writing of the report.

## Availability of data and materials

All data used in the discovery analyses are available from UK Biobank on application at <https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access>. Data from UK Biobank that are released to approved projects are de-identified with project specific identifiers assigned to individuals. The genome-wide summary statistics generated by the study are available on the GWAS Catalog (<https://www.ebi.ac.uk/gwas>) under accession ID GCST90267381.

## Declarations

### Ethics approval and consent to participate

This research was conducted using the UK Biobank resource under project application numbers 871 and 9072. UK Biobank has approval from the North West Multi-centre Research Ethics Committee (REC ref: 21/NW/0157), which operates according to the principles of the Declaration of Helsinki. UK Biobank approved projects operate under this ethics committee approval. Informed consent is provided by all participants in UK Biobank, and participants have the right to withdraw from the study at any time.

### Consent for publication

Not applicable.

### Competing interests

The authors declare no competing interests.

### Author details

<sup>1</sup>Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter EX2 5DW, UK. <sup>2</sup>Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at University of California, Los Angeles, CA 90024, USA. <sup>3</sup>Exeter Centre of Excellence for Diabetes Research, University of Exeter, Exeter EX2 5DW, UK. <sup>4</sup>Macleod Diabetes and Endocrinology Centre, Royal Devon and Exeter National Health Service Foundation Trust, Exeter EX2 5DW, UK.

Received: 14 December 2022 Accepted: 8 September 2023

Published online: 02 October 2023

## References

1. Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. *J Gen Intern Med*. 2008;23:1507–13.
2. Lobo RA. Hormone-replacement therapy: current thinking. *Nat Rev Endocrinol*. 2017;13(4):220–31.
3. Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flashes. *Front Neuroendocrinol*. 2013;34:211–27.
4. Krajewski-Hall SJ, Miranda Dos Santos F, McMullen NT, Blackmore EM, Rance NE. Glutamatergic neurokinin 3 receptor neurons in the median

- preoptic nucleus modulate heat-defense pathways in female mice. *Endocrinology*. 2019;160(4):803–16.
5. Prague JK, Roberts RE, Comninou AN, Clarke S, Jayasena CN, Nash Z, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flashes: a phase 2, randomised, double-blind, placebo-controlled trial. *Lancet*. 2017;389(10081):1809–20.
  6. Fraser GL, Lederman S, Waldbaum A, Kroll R, Santoro N, Lee M, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. *Menopause NY N*. 2020;27(4):382–92.
  7. Depypere H, Timmerman D, Donders G, Sieprath P, Ramael S, Combalbert J, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. *J Clin Endocrinol Metab*. 2019;104(12):5893–905.
  8. Trower M, Anderson RA, Ballantyne E, Joffe H, Kerr M, Pawsey S. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. *Menopause NY N*. 2020;27(5):498–505.
  9. Prague JK. Neurokinin 3 receptor antagonists—prime time? *Climacteric*. 2021;24(1):25–31.
  10. Navarro VM. Tachykinin signaling in the control of puberty onset. *Curr Opin Endocr Metab Res*. 2020;14:92–6.
  11. Young J, Bouligand J, Franco B, Raffin-Sanson ML, Gaille S, Jeanpierre M, et al. TAC3 and TACR3 defects cause hypothalamic congenital hypogonadotropic hypogonadism in humans. *J Clin Endocrinol Metab*. 2010;95(5):2287–95.
  12. Topaloglu AK, Reimann F, Guclu M, Yalin AS, Kotan LD, Porter KM, et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. *Nat Genet*. 2009;41(3):354–8.
  13. Lunetta KL, Day FR, Sulem P, Ruth KS, Tung JY, Hinds DA, et al. Rare coding variants and X-linked loci associated with age at menarche. *Nat Commun*. 2015;6:7756.
  14. Crandall CJ, Manson JE, Hohensee C, Horvath S, Wactawski-Wende J, LeBlanc ES, et al. Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the women's health initiative study. *Menopause*. 2017;24(3):252–61.
  15. Meijssen JJ, Shen H, Vemuri M, Rasgon NL, Koenen KC, Duncan LE. Shared genetic influences on depression and menopause symptoms. *Psychol Med*. 2023;53(6):2241–51.
  16. Day FR, Thompson DJ, Helgason H, Chasman DI, Finucane H, Sulem P, et al. Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. *Nat Genet*. 2017;49(6):834–41.
  17. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature*. 2018;562:203–9.
  18. Allen N, Sudlow C, Downey P, Peakman T, Danesh J, Elliott P, et al. UK Biobank: current status and what it means for epidemiology. *Health Policy Technol*. 2012;1(3):123–6.
  19. Writing Group for the Womens Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. *JAMA*. 2002;288(3):321–33.
  20. Frayling TM, Beaumont RN, Jones SE, Yaghootkar H, Tuke MA, Ruth KS, et al. A common allele in FGF21 associated with sugar intake is associated with body shape, lower total body-fat percentage, and higher blood pressure. *Cell Rep*. 2018;23(2):327–36.
  21. Loh PR, Tucker G, Bulik-Sullivan BK, Vilhjálmsson BJ, Finucane HK, Salem RM, et al. Efficient Bayesian mixed-model analysis increases association power in large cohorts. *Nat Genet*. 2015;47:284–90.
  22. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010;26(17):2190–1.
  23. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The ensemble variant effect predictor. *Genome Biol*. 2016;17(1):1–14.
  24. Yates AD, Achuthan P, Akanni W, Allen J, Allen J, Alvarez-Jarreta J, et al. Ensembl 2020. *Nucleic Acids Res*. 2020;48:D682–8.
  25. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res*. 2012;40(Database issue):D930–4.
  26. Wang D, Liu S, Warrell J, Won H, Shi X, Navarro FCP, et al. Comprehensive functional genomic resource and integrative model for the human brain. *Science*. 2018;362(6420):eaat8464.
  27. Nellore A, Jaffe AE, Fortin JP, Alquicira-Hernandez J, Collado-Torres L, Wang S, et al. Human splicing diversity and the extent of unannotated splice junctions across human RNA-seq samples on the sequence read archive. *Genome Biol*. 2016;17(1):1–14.
  28. Chang CC, Chow CC, Tellier LCM, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience*. 2015;4(1):s13742–015.
  29. Turner SD. qqman: an R package for visualizing GWAS results using Q-Q and manhattan plots. *J Open Source Softw*. 2018;3(25):731.
  30. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Glied TP, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics*. 2011;26(18):2336–7.
  31. Szustakowski JD, Balasubramanian S, Kvikstad E, Khalid S, Bronson PG, Sasson A, et al. Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. *Nat Genet*. 2021;53(7):942–8.
  32. Zhou W, Zhao Z, Nielsen JB, Fritsche LG, LeFaive J, Gagliano Taliun SA, et al. Scalable generalized linear mixed model for region-based association tests in large biobanks and cohorts. *Nat Genet*. 2020;52(6):634–9.
  33. Mbatchesou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, et al. Computationally efficient whole-genome regression for quantitative and binary traits. *Nat Genet*. 2021;53(7):1097–103.
  34. Gianetti E, Tusset C, Noel SD, Au MG, Dwyer AA, Hughes VA, et al. TAC3/TACR3 mutations reveal preferential activation of gonadotropin-releasing hormone release by neurokinin B in neonatal life followed by reversal in adulthood. *J Clin Endocrinol Metab*. 2010;95(6):2857–67.
  35. Wright CF, West B, Tuke M, Jones SE, Patel K, Laver TW, et al. Assessing the pathogenicity, penetrance, and expressivity of putative disease-causing variants in a population setting. *Am J Hum Genet*. 2019;104(2):275–86.
  36. Tyrrell J, Mulugeta A, Wood AR, Zhou A, Beaumont RN, Tuke MA, et al. Using genetics to understand the causal influence of higher BMI on depression. *Int J Epidemiol*. 2019;48(3):834–48.
  37. Day FR, Ruth KS, Thompson DJ, Lunetta KL, Pervjakova N, Chasman DI, et al. Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. *Nat Genet*. 2015;47(11):1294–303.
  38. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol*. 2016;40(4):304–14.
  39. Bowden J, Smith GD, Burgess S, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*. 2015;44(2):512–25.
  40. Prague JK, Roberts RE, Comninou AN, Clarke S, Jayasena CN, Mohideen P, et al. Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action. *Menopause NY N*. 2018;25(8):862–9.
  41. Jayasena CN, Comninou AN, Stefanopoulou E, Buckley A, Narayanaswamy S, Izzti-Engbeaya C, et al. Neurokinin B administration induces hot flashes in women. *Sci Rep*. 2015;5:1–7.
  42. Rance NE. Menopause and the human hypothalamus: Evidence for the role of kisspeptin/neurokinin B neurons in the regulation of estrogen negative feedback. *Peptides*. 2009;30(1):111–22.
  43. Franco B, Bouligand J, Voican A, Amazit L, Trabado S, Fagart J, et al. Normosmic congenital hypogonadotropic hypogonadism due to TAC3/TACR3 mutations: characterization of neuroendocrine phenotypes and novel mutations. *PLoS One*. 2011;6(10):e25614.
  44. Ruth KS, Day FR, Tyrrell J, Thompson DJ, Wood AR, Mahajan A, et al. Using human genetics to understand the disease impacts of testosterone in men and women. *Nat Med*. 2020;26(2):252–8.
  45. Ruth KS, Day FR, Hussain J, Martinez-Marchal A, Aiken CE, Azad A, et al. Genetic insights into biological mechanisms governing human ovarian ageing. *Nature*. 2021;596(7872):393–7.
  46. Malherbe P, Knoflach F, Marcuz A, Bohnert C, Weber M, Knust H, et al. Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: Biochemical and electrophysiological characterization. *Neuropharmacology*. 2014;86:259–72.

47. Crawford SL, Crandall CJ, Derby CA, El Khoudary SR, Waetjen LE, Fischer M, et al. Menopausal hormone therapy trends before versus after 2002: impact of the women's health initiative study results. *Menopause*. 2018;26(6):588–97.
48. National Institute for Health and Care Excellence. Menopause: diagnosis and management. NICE guideline. 2015.
49. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with the general population. *Am J Epidemiol*. 2017;186:1026–34.

### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

